Berning 2000.

Methods	Randomised placebo‐controlled trial
Participants	94 healthy non‐smoking women, 1 to 3 years following spontaneous menopause (mean 22 months), with body mass index < 27 kg/m2, free of diseases or medication known to influence calcium metabolism or to contraindicate the trial medication. Mean age: 53 years
Interventions	Tibolone 2.5 mg/d Tibolone 1.25 mg/d Placebo Administered for 2 years
Outcomes	Vaginal bleeding
Notes	Timing: unclear Location: Netherlands Multi‐centre: number of sites not specified
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Unclear what "random medication number" means
Allocation concealment (selection bias)	Unclear risk	Method not specified
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Although study authors do not state whether trial is double‐blind or single‐blind, they used identical looking interventions and a placebo control
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Not specified, but given the nature of the outcome assessed, evaluation is likely to be "objective"
Incomplete outcome data (attrition bias) All outcomes	Low risk	Bleeding: all randomised participants assessed
Selective reporting (reporting bias)	Unclear risk	Study protocol not available
Conflict of interest	High risk	Financed by the drug manufacturer. Study authors have conflicts of interest